• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma.

作者信息

Vesalainen S, Lipponen P, Talja M, Syrjänen K

机构信息

Department of Surgery, University of Kuopio, Finland.

出版信息

Eur J Cancer. 1994;30A(12):1797-803. doi: 10.1016/0959-8049(94)e0159-2.

DOI:10.1016/0959-8049(94)e0159-2
PMID:7880609
Abstract

A series of 325 prostatic adenocarcinomas with a long-term clinical follow-up were subjected to light microscopic analysis of histological prognostic factors, including three grading systems (Gleason score, WHO grade, nuclear grade), perineural infiltration of the tumour (PNI), tumour infiltrating lymphocytes (TIL) and the presence of apoptotic cells (APO). All three histological classifications correlated significantly with the prognosis, but in multivariate analysis, the Gleason score was superior to the WHO grading or nuclear grading in predicting patient survival. PNI was significantly related to poor differentiation of the tumour, its progression and ominous disease outcome, particularly in T1-2MO tumours. The density of TIL was independent of the tumour differentiation, and absent or weak TIL were signs of a high risk of tumour progression and of a fatal disease. Apoptotic cells were commonly detected in poorly differentiated tumours and apoptosis was related to disease progression and low survival probability. The results suggest that the Gleason score, PNI and the density of TIL should be included in routine pathology reports, to be used by clinicians while making therapeutic decisions in prostatic cancer.

摘要

相似文献

1
Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma.
Eur J Cancer. 1994;30A(12):1797-803. doi: 10.1016/0959-8049(94)e0159-2.
2
A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour.
Anticancer Res. 1996 Jul-Aug;16(4A):2095-100.
3
Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma.肿瘤血管生成及基底膜结构作为T1-2MO期前列腺腺癌的预后因素
Anticancer Res. 1994 Mar-Apr;14(2B):709-14.
4
Mitotic activity and prognosis in prostatic adenocarcinoma.前列腺腺癌的有丝分裂活性与预后
Prostate. 1995 Feb;26(2):80-6. doi: 10.1002/pros.2990260204.
5
Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.前列腺腺癌的进展与生存:临床分期、Gleason分级、S期分数和DNA倍体的比较
Br J Cancer. 1994 Aug;70(2):309-14. doi: 10.1038/bjc.1994.298.
6
Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology.T1-3M0期前列腺腺癌的初始治疗结果取决于肿瘤生物学特性。
Anticancer Res. 1995 Mar-Apr;15(2):569-73.
7
Prognostic factors in prostatic adenocarcinoma assessed by means of quantitative histology.通过定量组织学评估前列腺腺癌的预后因素。
Eur Urol. 1991;19(4):274-8. doi: 10.1159/000473642.
8
Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.淋巴管浸润是前列腺腺癌的一个独立预后因素。
J Urol. 2005 Dec;174(6):2181-5. doi: 10.1097/01.ju.0000181215.41607.c3.
9
Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer.肿瘤浸润淋巴细胞作为移行细胞膀胱癌的独立预后因素
Eur J Cancer. 1992;29A(1):69-75. doi: 10.1016/0959-8049(93)90579-5.
10
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.局部晚期前列腺癌男性患者中短期雄激素抑制联合放疗与中期雄激素抑制联合放疗、联合或不联合唑来膦酸的比较(TROG 03.04 RADAR):一项开放标签、随机、3 期析因试验。
Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

引用本文的文献

1
Prognostic value of tumour-associated regulatory T-cells as a biomarker in non-small cell lung cancer: a systematic review and meta-analysis.肿瘤相关调节性 T 细胞作为非小细胞肺癌生物标志物的预后价值:系统评价和荟萃分析。
Syst Rev. 2024 Sep 14;13(1):233. doi: 10.1186/s13643-024-02642-w.
2
Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression.前列腺癌发生前和发生后的 B 细胞淋巴细胞表达变化模式与前列腺癌的进展有关。
Cancer Med. 2024 Mar;13(6):e7118. doi: 10.1002/cam4.7118.
3
Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study.
前列腺导管内癌的白细胞浸润:一项探索性研究。
Cancers (Basel). 2023 Apr 9;15(8):2217. doi: 10.3390/cancers15082217.
4
Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer.探索宫颈癌的新型基因与细胞治疗方法。
Cancers (Basel). 2022 Dec 30;15(1):263. doi: 10.3390/cancers15010263.
5
Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.免疫检查点 STING 和 MHCII 在小细胞肺癌中的蛋白表达。
Cancer Immunol Immunother. 2023 Mar;72(3):561-578. doi: 10.1007/s00262-022-03270-w. Epub 2022 Aug 17.
6
Depleting Ly6G Positive Myeloid Cells Reduces Pancreatic Cancer-Induced Skeletal Muscle Atrophy.耗竭 Ly6G 阳性髓系细胞可减少胰腺癌诱导的骨骼肌萎缩。
Cells. 2022 Jun 10;11(12):1893. doi: 10.3390/cells11121893.
7
Decreased levels of cathepsin Z mRNA expressed by immune blood cells: diagnostic and prognostic implications in prostate cancer.免疫血细胞中组织蛋白酶 Z mRNA 水平降低:在前列腺癌中的诊断和预后意义。
Braz J Med Biol Res. 2021 Aug 6;54(10):e11439. doi: 10.1590/1414-431X2021e11439. eCollection 2021.
8
N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells.N-钙黏蛋白抑制剂创造了一个微环境,使肿瘤浸润淋巴细胞免受免疫检查点和 Treg 细胞的影响。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002138.
9
The immunotherapy revolution in genitourinary malignancies.泌尿生殖系统恶性肿瘤的免疫治疗革命。
Immunotherapy. 2020 Aug;12(11):819-831. doi: 10.2217/imt-2020-0054. Epub 2020 Jun 29.
10
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.新型 5T4 病毒载体疫苗接种方案在早期前列腺癌中的安全性和免疫原性:一项 I 期临床试验。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000928.